In South Africa, a country of 60 million people, not a single medical device is registered with the national regulator. The South African Health Products Regulatory Authority licenses the companies that manufacture, import and distribute devices, but the product registration system it has promised since 2017 is still being piloted. Meanwhile, Nigeria's drug and device regulator processes applications through a portal it only fully digitized in the past two years, Kenya requires every device maker to have named a local pharmacovigilance officer by December 31, 2025, and Egypt just rewrote six categories of its device dossier requirements in a single February 2026 notice.
None of these four regulators run the same system, use the same timelines, or recognize each other's approvals by default. For a life sciences or medtech company trying to reach patients across the continent, that fragmentation is the actual compliance workload, not any single country's rulebook.
Here is what is really changing in Africa's four largest life sciences markets in 2026, and where continental efforts are (and are not) closing the gaps between them.
Which regulators actually decide medical device market access in Africa?
Four national authorities dominate practical market access: South Africa's SAHPRA, Nigeria's NAFDAC, Kenya's Pharmacy and Poisons Board, and Egypt's Egyptian Drug Authority. Each classifies devices differently, runs its own submission portal, and sets its own fees and timelines, and none of them defers automatically to the others' decisions.
SAHPRA, created in 2018 under the Medicines and Related Substances Act of 1965, currently regulates devices almost entirely through establishment licensing rather than product registration: any company that manufactures, imports, distributes or wholesales a device in South Africa needs a Medical Device Establishment Licence, but the device itself is not yet formally registered in most cases. NAFDAC requires every device to go through its NAFDAC Automated Product Administration and Monitoring System, with Class A devices reviewed within a maximum of 120 working days and Classes B through D within 240 working days. Kenya's PPB uses a four-tier risk classification, Class A through D, aligned to IMDRF principles, with review routes ranging from a 6 to 12 month full evaluation down to 48 hour immediate registration for devices already cleared by at least three reference regulators. Egypt's EDA classifies under an EU MDR-aligned system through its MeDevice portal, launched in July 2021, with standard review running 4 to 10 months and a fast track available for CE-marked or FDA-cleared devices.
What is changing in South Africa's device registration system in 2026?
SAHPRA is phasing in mandatory ISO 13485 certification for every establishment licence holder, and Phase 3 of that rollout took effect April 1, 2026. Under the September 2025 SAHPRA communication (Issue No. MD01-2025/2026_v2), all existing licence holders must now have a valid ISO 13485:2016 certificate available for verification during audits, complaint investigations or vigilance activities, whether or not their licence is up for renewal. The certification requirement tightens further in June 2027, when it becomes mandatory for licence amendments and product list updates, and again in April 2028, when it applies to every new application.
Separately, SAHPRA published its Medical Devices Reliance Guideline, document SAHPGL-MD-22, on February 25, 2026. The guideline formalizes how SAHPRA will lean on approvals already granted by recognized authorities, including the FDA, the EU, Australia's TGA, Japan's PMDA, Health Canada, Brazil's ANVISA and WHO prequalification, when it eventually rolls out full product registration under its long-promised Registration Call-Up Plan. A voluntary feasibility study for that registration system, launched in May 2024 and covering high-risk devices and IVDs including HIV and TB tests, produced an updated report in March 2026. Until the call-up plan is published, however, no medical device sold in South Africa carries a SAHPRA product registration number.
| Date | Jurisdiction | Development |
|---|---|---|
| December 31, 2025 | Kenya | QPPV appointment deadline for all marketing authorization holders |
| February 12, 2026 | Egypt | EDA procedural facilitations across six dossier requirement areas |
| February 15, 2026 | African Union | AU leaders renew call for universal AMA Treaty ratification |
| February 25, 2026 | South Africa | SAHPRA publishes Medical Devices Reliance Guideline (SAHPGL-MD-22) |
| March 2026 | South Africa | Updated device registration feasibility study report published |
| April 1, 2026 | South Africa | ISO 13485 Phase 3 in effect for all existing licence holders |
Why does Nigeria still require every device to be individually registered before sale?
Because the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria 2004, and NAFDAC's Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations 2024 make registration mandatory for every device sold, imported or distributed in Nigeria, and neither instrument recognizes automatic reliance on a foreign approval. A foreign manufacturer must appoint a local agent or importer of record, submit a device dossier through the NAPAMS portal after a dossier screening clearance, and provide evidence of Good Manufacturing Practice, labeling, intended use and, for higher risk classes, laboratory testing of samples imported under a specific permit.
The 2024 regulation also set the current fee schedule, which charges a flat 30,000 naira for medical device registration compared with 70,000 naira for a pharmaceutical drug, and confirmed that a registration certificate is valid for five years. What has not changed is the structural bottleneck: a separate application is required for each individual product, product group, product family or system, so a manufacturer with a broad device portfolio faces dozens of parallel NAPAMS submissions rather than one umbrella filing, each running its own 120 or 240 working day clock that pauses entirely if NAFDAC issues a Compliance Directive mid-review.
Is there a single African regulator that companies can register with instead of going country by country?
Not yet, and the continent's answer, the African Medicines Agency, is still building toward the scale it needs. The AMA Treaty entered into force on November 5, 2021 after its 15th ratification, and headquarters opened in Kigali, Rwanda. As of December 2025, 31 of the African Union's 55 member states had ratified the treaty, and at a February 15, 2026 meeting in Addis Ababa, AU leaders again urged the remaining 24 to ratify without delay, with AMA's Director-General warning that fewer than 35 ratifications limits how far the agency's reliance mechanisms can reach.
South Africa, Nigeria, Kenya and Egypt, the four markets covered here, are not among the confirmed ratifiers as of this writing, which means AMA's planned Continental Listing of Human Medicinal Products and its joint scientific assessments do not yet bind their national registration decisions. A separate, older mechanism, the WHO-hosted African Vaccine Regulatory Forum, has run since 2006 and does deliver real reliance in practice: its joint reviews have cleared clinical trial applications for products including the RTS,S malaria vaccine and multiple COVID-19 vaccines, with participating regulators reaching consensus decisions in 10 to 15 days during public health emergencies. AVAREF's mandate now extends beyond vaccines to medical products and devices generally, and it is formally recognized as a technical committee feeding into AMA's own operationalization. A compliance strategy for Africa in 2026 has to track both tracks: the slow-moving treaty ratification story and the AVAREF joint reviews that already move faster than most national pathways alone. Obsidian's jurisdiction-level monitoring keeps both threads on one timeline, so a shift in AMA ratification status or a new AVAREF joint review does not sit buried in a regional news digest.
What should a life sciences compliance team in Africa be doing right now?
Confirm ISO 13485 certificates are current and cover every manufacturing site listed on a SAHPRA establishment licence, since Phase 3 verification is already live and Phase 4 tightens the requirement further in June 2027. Audit whether Kenyan marketing authorizations have a named, operational QPPV, given the PPB's December 31, 2025 deadline has already passed and non-compliance risks suspension of existing registrations. Map every Nigerian device SKU against its own NAPAMS submission rather than assuming portfolio-level registration, and revisit Egyptian dossiers against the EDA's February 2026 facilitations on free sale certificates, registration samples and shelf life documentation before resubmitting anything under the old process.
Running that checklist by hand across four regulators, a continental treaty tracker, and an active WHO-hosted forum is exactly the kind of fragmented monitoring that costs a compliance team days every quarter. Obsidian tracks SAHPRA, NAFDAC, the PPB and the EDA on tier-0 official sources, with alerts the moment a call-up plan, a new reliance guideline or a fee schedule changes, so a regulatory lead sees the update the day it publishes rather than the week a consultant's newsletter picks it up. For teams also weighing whether a specific device qualifies for Kenya's expedited or immediate registration routes, Obsidian's AI companion can walk through the same verified source records referenced in this article, and organizations building internal regulatory tooling can pull that data directly through the MCP. Teams ready to move from tracking one region to tracking Africa's full four-market patchwork can start with a plan scoped to exactly the jurisdictions covered here.